Michael T Meister
Overview
Explore the profile of Michael T Meister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
165
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
van Belzen I, van Tuil M, Badloe S, Janse A, Verwiel E, Santoso M, et al.
Cell Genom
. 2024 Oct;
4(11):100675.
PMID: 39406233
In pediatric cancer, structural variants (SVs) and copy-number alterations contribute to cancer initiation as well as progression, thereby aiding diagnosis and treatment stratification. Although suggested to be of importance, the...
2.
Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J, et al.
NPJ Precis Oncol
. 2024 Sep;
8(1):210.
PMID: 39322659
No abstract available.
3.
Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):172.
PMID: 39097671
Liquid biopsies are emerging as an alternative source for pediatric cancer biomarkers with potential applications during all stages of patient care, from diagnosis to long-term follow-up. While developments within this...
4.
Heim C, Moser L, Kreyenberg H, Bonig H, Tonn T, Wels W, et al.
Front Immunol
. 2023 Sep;
14:1228894.
PMID: 37662907
Introduction: Metastatic rhabdomyosarcoma (RMS) is a challenging tumor entity that evades conventional treatments and endogenous antitumor immune responses, highlighting the need for novel therapeutic strategies. Applying chimeric antigen receptor (CAR)...
5.
DeMartino J, Meister M, Visser L, Brok M, Groot Koerkamp M, Wezenaar A, et al.
Nat Commun
. 2023 May;
14(1):3074.
PMID: 37244912
Paediatric rhabdomyosarcoma (RMS) is a soft tissue malignancy of mesenchymal origin that is thought to arise as a consequence of derailed myogenic differentiation. Despite intensive treatment regimens, the prognosis for...
6.
de Vries I, Ewijk R, Adriaansen L, Bohte A, Braat A, Davila Fajardo R, et al.
Pediatr Radiol
. 2023 Mar;
53(5):1043.
PMID: 36930287
No abstract available.
7.
de Vries I, Ewijk R, Adriaansen L, Bohte A, Braat A, Davila Fajardo R, et al.
Pediatr Radiol
. 2023 Feb;
53(4):788-812.
PMID: 36843091
Rhabdomyosarcoma, although rare, is the most frequent soft tissue sarcoma in children and adolescents. It can present as a mass at nearly any site in the body, with most common...
8.
Langenberg K, Meister M, Bakhuizen J, Boer J, van Eijkelenburg N, Hulleman E, et al.
Eur J Cancer
. 2022 Oct;
175:311-325.
PMID: 36182817
iTHER is a Dutch prospective national precision oncology program aiming to define tumour molecular profiles in children and adolescents with primary very high-risk, relapsed, or refractory paediatric tumours. Between April...
9.
Meister M, Groot Koerkamp M, de Souza T, Breunis W, Frazer-Mendelewska E, Brok M, et al.
EMBO Mol Med
. 2022 Aug;
14(10):e16001.
PMID: 35916583
Rhabdomyosarcomas (RMS) are mesenchyme-derived tumors and the most common childhood soft tissue sarcomas. Treatment is intense, with a nevertheless poor prognosis for high-risk patients. Discovery of new therapies would benefit...
10.
Erdogdu U, Dolgikh N, Laszig S, Sarchen V, Meister M, Wanior M, et al.
Neoplasia
. 2021 Dec;
24(2):109-119.
PMID: 34959030
BH3 mimetics are promising novel anticancer therapeutics. By selectively inhibiting BCL-2, BCL-x, or MCL-1 (i.e. ABT-199, A-1331852, S63845) they shift the balance of pro- and anti-apoptotic proteins in favor of...